February 17, 2017 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Cynosure, Inc. (NASDAQ:CYNO), was announced concerning whether the takeover of Cynosure, Inc. by Hologic, Inc for $66.00 per share. is unfair to NASDAQ:CYNO stockholders.

The investigation by a law firm concerns whether certain officers and directors of Cynosure, Inc. (NASDAQ:CYNO breached their fiduciary duties owed to Cynosure, Inc. investors in connection with the proposed acquisition.

On February 14, 2017, Hologic, Inc. (Nasdaq: HOLX), a leader in women's health, and Cynosure, Inc. (NASDAQ:CYNO) announced they have signed an agreement for Hologic to acquire all outstanding Cynosure, Inc. (NASDAQ:CYNO) shares for $66.00 per share in cash, which corresponds to an equity value of approximately $1.65 billion and an enterprise value of $1.44 billion net of cash.

However, given that following the takeover announcement NASDAQ:CYNO shares rose in the open market to as high as $66.50 per share on February 15, 2017, the investigation concerns whether the offer is unfair to NASDAQ:CYNO stockholders. More specifically, the investigation concerns whether the Cynosure Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

Cynosure, Inc. reported that its annual Total Revenue rose from $226.01 million in 2013 to $433.53 million in 2016 and that its Net Loss of $1.65 million in 2013 turned into a Net Income fo $15.42 million in 2016.

On February 17, 2017, NASDAQ:CYNO shares closed at $66.25 per share.